Publications

 

List of publications and relevant citations:

  1. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002;186:1558-64.
  2. Page-Shafer K, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. J Acquir Immune Defic Syndr 2002;31:422-31.
  3. Lum PJ, Ochoa KC, Hahn JA, Page Shafer K, Evans JL, Moss AR. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study. Am J Public Health 2003;93:919-23.
  4. Bacon O, Lum P, Hahn J, et al. Commercial Sex Work and Risk of HIV Infection Among Young Drug-Injecting Men Who Have Sex With Men in San Francisco.Sex Transm Dis 2006;33:228-34.
  5. Davidson PJ, Ochoa KC, Hahn JA, Evans JL, Moss AR. Witnessing heroin-related overdoses: the experiences of young injectors in San Francisco. Addiction 2002;97:1511-6.
  6. Ochoa KC, Davidson PJ, Evans JL, Hahn JA, Page-Shafer K, Moss AR. Heroin overdose among young injection drug users in San Francisco. Drug Alcohol Depend 2005;e-pub.
  7. Evans JL, Hahn JA, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health 2003;80:137-46.
  8. Bourgois P, Prince B, Moss A. The Everyday Violence of Hepatitis C Among Young Women Who Inject Drugs in San Francisco. Hum Organ 2004;63:253-64.
  9. Page-Shafer K, Pappalardo BL, Tobler LH, et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 2008;46:499-506.
  10. Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS 2007;21:1967-9.
  11. Page K, Hahn J, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution and reinfection. Journal of Infectious Diseases in press.
  12. Lum PJ, Hahn JA, Page-Shafer K, et al. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat 2008;15:229-36.
  13. Inglez-Dias A, Hahn JA, Lum PJ, Evans J, Davidson P, Page-Shafer K. Trends in methamphetamine use in young injection drug users in San Francisco from 1998 to 2004: the UFO Study. Drug Alcohol Rev 2008;27:286-91.
  14. Hahn JA, Page-Shafer K, Ford J, Paciorek A, Lum PJ. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug Alcohol Depend 2008;93:43-50.
  15. Evans JL, Hahn JA, Lum PJ, Stein ES, Page K. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug Alcohol Depend 2009;101:152-7.
  16. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009 Oct 15;200(8):1216-26.
  17. Cox AL, Page K, Bruneau J, et al. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology. 2009;136:26-31.
  18. Levy V, Evans JL, Stein ES, Davidson PJ, Lum PJ, Hahn JA, Page K. Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? Vaccine. 2010; 28(37):5947-51.
  19. Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. Addiction. 2010; 105(7):1254-64.
  20. Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infectious Diseases. 2011; 11:208.

  21. Evans J, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. American Journal of Epidemiology. 2012.
  22. Montgomery ME, Fatch RS, Evans JL, Yu M, Davidson PJ, Page K, Hahn JA. Injecting risk behavior among traveling young injection drug users: travel partner and city characteristics. J Urban Health. 2013; 90(3):500-15.
  23. Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, Delwart E, Tobler L, Cox AL, Busch MP. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clinical Infectious Diseases. 2013; 56(3):405-13.
  24. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clinical Infectious Diseases. 2013; 57 Suppl 2:S32-8.
  25. Briceno A, Morris MD, Evans J, Raymond FH, Page K. Characteristics and Health Service Utilization in Two Samples of Young Injection Drug Users Recruited Using Direct and Referral Methods in San Francisco, California. Journal of Alcoholism and Drug Dependence. 2013; 1:5.
  26. Dokubo EK, Evans JL, Winkelman V, Syrus S, Tobler LH, Asher A, Briceno A, Page K. Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. Journal of Clinical Virology. 2014; 59(4):223-7.
  27. Evans J, Morris MD, Yu M, Page K, Hahn JA. Concordance of Risk Behavior Reporting within HCV Serodiscordant Injecting Partnerships of Young Injection Drug Users in San Francisco, CA. Drug and Alcohol Dependence. 2014; 142:239-44.
  28. Tracy D, Hahn JA, Fuller LC, Evans J, Briceno A, Morris MD, Lum PJ, Page K. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open. 2014; 4(5):e004988.
  29. Hayes B, Briceno A, Asher A, Yu M, Evans JL, Hahn JA, Page K. Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. BMC Public Health. 2014; 14(1):645.
  30. Jain J, Evans J, Briceno A, Page K, Hahn JA. Comparison of phosphatidylethanol results to self-reported alcohol consumption among young injection drug users. Alcohol and Alcoholism. 2014; 9(5):520-4.
  31. Tsui JI, Evans J, Lum PJ, Hahn JA, Page K. Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users. JAMA Internal Medicine. 2014; 74(12):1974-81.
  32. Morris MD, Evans J, Montgomery M, Yu M, Briceno A, Page K, Hahn JA. Intimate Injection Partnerships Are at Elevated Risk of High-Risk Injecting: A Multi-Level Longitudinal Study of HCV-Serodiscordant Injection Partnerships in San Francisco, CA. PLoS ONE. 2014; 9(10):e109282.
  33. Mirzazadeh A, Grasso M, Johnson K, Briceno A, Navadeh S, McFarland W, Page K. Acceptability of Global Positioning System technology to survey injecting drug users' movements and social interactions: A pilot study from San Francisco, USA. Technol Health Care. 2014 Jan 1; 22(5):689-700
  34. Mirzazadeh A, Evans J, Jain J, Hahn J, Shiboski S, Lum P, Bentsen Ch, Davis G, Shriver K, Dimpasoc M, Stone M, Busch M, Page K. Racial and ethnic disparities in HIV incidence in young adults who inject drugs in San Francisco: an observational study of HIV incidence and risk behaviors from 2000-2014. Abstract IAS 2015
  35. Mirzazadeh A, Evans JL, Hahn JA, Jain J, Briceno A, Shiboski S, Lum PJ, Bentsen C, Davis G, Shriver K, Dimapasoc M, Stone M, Busch MP, Page K. Continued Transmission of HIV Among Young Adults Who Inject Drugs in San Francisco: Still Room for Improvement. AIDS Behav. 2017 Nov 22.